Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma

References

• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.
   PubMed Web of Science ®Google Scholar
• Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol 2003;8:200–206.
   PubMedGoogle Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Yata K, Otsuki T, Kurebayashi J, et al. Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells. Int J Oncol 2003;22:165–173.
   PubMed Web of Science ®Google Scholar
• Vacca A, Scavelli C, Montefusco V, et al. Thalidomide down regulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005;23: 5334–5346.
   PubMed Web of Science ®Google Scholar
• Dmoszyńska A, Bojarska-Junak A, Domański D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002;43:401–406.
   PubMed Web of Science ®Google Scholar
• Neben K, Moehler T, Egerer G, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001;7:2675–2681.
   PubMed Web of Science ®Google Scholar
• Terpos E, Anargyrou K, Katodritou E, et al. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 2012;130:735–742.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sattler M, Tonon G, et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res 2009;69:5082–5090.
   PubMed Web of Science ®Google Scholar
• Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105:3286–3294.
   PubMed Web of Science ®Google Scholar
• Bhaskar A, Gupta R, Kumar L et al. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leuk Lymphoma 2012;53:635–640.
   PubMed Web of Science ®Google Scholar
• Koh GY, Kim I, Kwak HJ, et al. Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp Mol Med 2002;34:1–11.
   PubMed Web of Science ®Google Scholar
• Chavakis E, Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 2002;22:887–893.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;2:116–129.
   Web of Science ®Google Scholar
• Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT–TIe2 pathway in malignancy. Nat Rev Cancer 2010;10:575–585.
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–1998.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders:a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Bhatti SS, Kumar L, Dinda AK, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol 2006;81:649–656.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau J-L, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Pour L, Svachova H, Adam Z et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 2010;89:385–389.
   PubMed Web of Science ®Google Scholar
• Colla S, Tagliaferri S, Morandi F et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity:involvement in myeloma-induced angiogenesis. Blood 2007;110:4464–4475.
   PubMed Web of Science ®Google Scholar
• Hata K, Nakayama K, Fujiwaki R, et al. Expression of the angiopoietin-1, angiopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004;93:215–222.
   PubMed Web of Science ®Google Scholar
• Ochiumi T, Tanaka S, Oka S, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 2004;24:539–547.
   PubMed Web of Science ®Google Scholar
• Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441: 437–443.
   PubMed Web of Science ®Google Scholar
• Takenaga K. Angiogenic signaling aberrantly induced by tumor hypoxia. Front Biosci 2011;16:31–48.
   Web of Science ®Google Scholar
• Veschini L, Belloni D, Foglieni C, et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007;109:2565–2570.
   PubMed Web of Science ®Google Scholar
• Ribbatti D. Tyrosine kinase inhibitors as antiangiogenic drugs in multiple myeloma. Pharmaceuticals 2010;3:1225–1231.
   Google Scholar
• Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23:2222–2232.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Magarotto V. Novel treatment paradigm for elderly patients with multiple myeloma. Am J Blood Res 2011;1:190–204.
   PubMedGoogle Scholar
• Prince HM, Hönemann D, Spencer A, et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009;113:4819–4820.
   PubMed Web of Science ®Google Scholar